Cell type-focused compound screen in human organoids reveals CK1 and MAPK11 inhibition protects cone photoreceptors from death

Stefan E Spirig,Valeria J Arteaga-Moreta,Zoltan Raics,Susana Posada-Céspedes,Stephanie Chreng,Olaf Galuba,Inga Galuba,Isabelle Claerr,Steffen Renner,Larissa Utz,Timo Kleindienst,Adrienn Volak,Jannick Imbach,Svitlana Malysheva,Rebecca A. Siwicki,Vincent Hahaut,Yanyan Hou,Simone Picelli,Marco Cattaneo,Josephine Jüttner,Cameron S Cowan,Myriam Duckely,Daniel K Baeschlin,Magdalena Renner,Vincent Unterreiner,Botond Roska

DOI: https://doi.org/10.1101/2023.10.09.561525

2024-10-19

Abstract:Human organoids that mirror their corresponding organs in cell-type diversity present an opportunity to perform large-scale screens for compounds that protect disease-affected or damage healthy cell types. However, such screens have not yet been performed. Here, we generated 20,000 human retinal organoids with GFP-labeled cone photoreceptors. Since degeneration of cones is a leading cause of blindness, we induced cone death and screened 2,707 compounds with known targets, for those that saved cones or those that further damaged cones. We identified inhibitors of CK1 or MAPK11 that protected cones, HSP90 inhibitors that saved cones in the short term but damaged them in the longer term, and broad HDAC inhibition by many compounds that significantly damaged cones. This work provides a database for cone-damaging compounds and describes compounds that can be starting points to develop neuroprotection for cones in diseases such as macular degeneration.

Neuroscience